Raxofelast (IRFI 016) is a hydrophilic vitamin E-like antioxidant, that was developed to maximize the antioxidant potency of phenols related to vitamin E. It has been investigated as a mucoactive drug, a type of drug that is used for treatment of respiratory diseases. Also, in diabetic mice, raxofelast was shown to improve wound healing to a level close to that seen in healthy mice, and in another study it improved clinical outcomes in experimental burn wounds. In a rat model of myocardial damage, raxofelast was found to be a useful drug to reduce heart attacks. This compound has good bioavailability and physicochemical properties. No clinical trials have been conducted.